ArticleEquine veterinary journal2026
Reining in strangles: Absence of disease in horses vaccinated with a DIVA-compatible recombinant fusion protein vaccine, Strangvac, following natural exposure to Streptococcus equi subspecies equi.
Article in Equine veterinary journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Antibody Titres to StrangvacVaccines · 2026Article
- Development and Immunogenicity of a Five-Antigen Strangles Vaccine Based on Equine Ferritin Nanoparticles in Mice.Veterinary sciences · 2026Article
- Reining in strangles: Absence of disease in horses vaccinated with a DIVA-compatible recombinant fusion protein vaccine, Strangvac, following natural exposure to Streptococcus equi subspecies equi.Equine veterinary journal · 2026Article
- Closing the Stable Door on Strangles: Serological Responses of Vaccinated Horses on a Farm Following the Arrival of a New Horse.Animals : an open access journal from MDPI · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundStrangles, caused by Streptococcus equi subspecies equi (S. equi), is a prevalent infectious disease of horses. This is the first report on the use of a new vaccine, Strangvac, in a natural outbreak of strangles.
objectivesTo measure the effects of Strangvac vaccination during an outbreak of strangles at a Swedish farm. STUDY
designLongitudinal cohort study.
methodsHealthy horses (n = 17) were vaccinated on day 0, which occurred 23 days after strangles was first confirmed in three unvaccinated horses on the same farm. Blood serum samples were collected on day 0, day 28 and day 489. A combined iELISA was used to measure total antibody titres towards the components of the vaccine. Specific antibody levels in blood sera to S. equi were also quantified using the antigen A/C iELISAs, which can differentiate infected from vaccinated animals. Clinical signs were monitored.
resultsAll vaccinated horses had increased total antibody titres to CCE, Eq85 and/or IdeE from day 0 (2.50 ± 0.28) to day 28 (3.63 ± 0.31; p < 0.0001). Seropositivity in the antigen A/C iELISA was noted in 8/17 healthy horses on day 0 (prior to vaccination), in 9/16 vaccinates on day 28, and in 3/3 unvaccinated clinical cases on day 28. None of the vaccinated horses developed strangles, but 5/7 of the original vaccinated horses tested seropositive in the A/C iELISA on day 489, which was 377 days after their third vaccination. MAIN LIMITATIONS: Aside from the three unvaccinated clinical cases, no unvaccinated control group was available.
conclusionsDespite adherence to recommended biosecurity measures, serological evidence of exposure to S. equi was demonstrated in half of the vaccinated horses. Notably, all horses vaccinated during the outbreak responded to the vaccine components and remained healthy, suggesting a protective effect of vaccination of healthy horses with Strangvac in outbreak situations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.